BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
argenx
ARGX
$43.6B
| $343M | 5.56% | 632,829 -59,045 | -9% | -$32M |
|
2
Ionis Pharmaceuticals
IONS
$6.8B
| $315M | 5.11% | 7,874,400 -386,034 | -5% | -$15.5M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $266M | 4.31% | 571,406 -22,055 | -4% | -$10.3M |
|
4
Intuitive Surgical
ISRG
$170B
| $244M | 3.95% | 496,775 -43,129 | -8% | -$21.2M |
|
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $223M | 3.61% | 809,095 -110,739 | -12% | -$30.5M |
|
6
Revolution Medicines
RVMD
$7.1B
| $221M | 3.58% | 4,871,360 -157,740 | -3% | -$7.15M |
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $215M | 3.48% | 1,863,800 -34,840 | -2% | -$4.01M |
|
8
Boston Scientific
BSX
$156B
| $206M | 3.33% | 2,452,797 -116,791 | -5% | -$9.79M |
|
|
9
Abbott
ABT
$231B
| $199M | 3.22% | 1,743,938 +137,785 | +9% | +$15.7M |
|
10
Stryker
SYK
$150B
| $190M | 3.08% | 526,607 -19,327 | -4% | -$6.98M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $182M | 2.95% | 2,485,627 +14,342 | +0.6% | +$1.05M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $166M | 2.69% | 3,735,915 -143,633 | -4% | -$6.38M |
|
13
Incyte
INCY
$16.5B
| $142M | 2.3% | 2,150,551 -2,953 | -0.1% | -$195K |
|
14
UnitedHealth
UNH
$281B
| $132M | 2.14% | 225,550 +19,875 | +10% | +$11.6M |
|
15
Moderna
MRNA
$9.37B
| $107M | 1.73% | 1,600,836 +37,101 | +2% | +$2.48M |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $104M | 1.69% | 3,071,615 +100,000 | +3% | +$3.4M |
|
17
Biohaven
BHVN
$1.63B
| $102M | 1.65% | 2,040,853 | – | – |
|
|
18
Exact Sciences
EXAS
$8.98B
| $98.7M | 1.6% | 1,449,465 +290,585 | +25% | +$19.8M |
|
19
CareDx
CDNA
$727M
| $98.2M | 1.59% | 3,145,456 -767,119 | -20% | -$24M |
|
20
Insulet
PODD
$23.9B
| $98.1M | 1.59% | 421,479 -13,941 | -3% | -$3.24M |
|
21
Medtronic
MDT
$119B
| $90.8M | 1.47% | 1,008,633 +6,886 | +0.7% | +$620K |
|
22
Becton Dickinson
BDX
$55.3B
| $81.4M | 1.32% | 337,633 -9,700 | -3% | -$2.34M |
|
23
Tandem Diabetes Care
TNDM
$845M
| $78.5M | 1.27% | 1,850,891 +307,624 | +20% | +$13M |
|
|
24
Evolent Health
EVH
$1.12B
| $75.5M | 1.22% | 2,670,050 +1,000,215 | +60% | +$28.3M |
|
25
Edwards Lifesciences
EW
$47.8B
| $74.8M | 1.21% | 1,134,076 -126,385 | -10% | -$8.34M |
|